Logo-jrip
ePublished: 04 Jun 2017
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2017;6(4): 264-268.
doi: 10.15171/jrip.2017.50

Scopus ID: 85040728178
  Abstract View: 1933
  PDF Download: 968

Original Article

Relationship of circulating levels of 25(OH)D with parathyroid hormone in various stages of chronic kidney disease

Mojgan Jalalzadeh 1,2 * , Seyed Nouraddin Mousavinasab 3, Ali Rostami 4

1 Departmentof Nephrology, Loghman Hakim Hospital, Shahid-Beheshti University of Medical Sciences, Tehran, Iran
2 Metabolic Disorder Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
3 Departmentof Biostatistics, Mazandaran University of Medical Sciences, Sari, Iran
4 Departmentof Nephrology, Modarres Hospital, Shahid-Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding author: Mojgan Jalalzadeh, Email: jmojgan1341@gmail.com

Abstract

Introduction: Vitamin D deficiency is common in both general population and chronic kidney disease (CKD) patients.

Objectives: The aim of this study was to compare 25(OH)D3 levels in stages 2 to 5 of CKD patients and to evaluate whether inactive vitamin D supplement could prevent increasing of serum PTH levels.

Patients and Methods: A total of 58 stages 2-4 CKD and 57 stage 5 CKD hemodialysis (HD) patients who had 25(OH)D3 <30 ng/mL were considered. All cases were under appropriate treatment for preventing secondary hyperparathyroidism. At the beginning, serum levels of vitamin D3, intact parathyroid hormone (iPTH), calcium (Ca), phosphate (P), alkaline phosphate (ALP) and albumin were measured. Patients received 300 000 IU/IM vitamin D3 and after 2 months this dosage was repeated, if it was necessary. All biochemical markers were checked and the effect of vitamin D3 was evaluated.

Results: At base line, serum levels of 25(OH)D3 and PTH in patients with stages 2 to 5 of CKD were; 14.85±7.8 ng/mL (stage 2), 70.8±16.8 pg/mL (stage 2); 16.48±7.8 ng/mL (stage 3), 69.6±39.2 pg/mL (stage 3); 16.33±8.1 ng/mL (stage 4), 123.74±92.5 pg/mL (stage 4); and 13.86±6.5 ng/mL (stage 5) and 567.23±276.7 pg/mL (stage 5), respectively. Two months after injections, 25(OH)D3 and PTH were changed as follow; 28.62 ng/mL (P=0.001) (stage 2), 59.38 pg/mL (P=0.34) (stage 2); 37.79 ng/mL (P<0.001) (stage 3), 62.41 pg/ml (P=0.18) (stage 3); 31.14 ng/mL (P=0.001) (stage 4), 91.02±69.4 pg/mL (P=0.003) (stage 4) and 48.48 ng/mL (P<0.001) (stage 5) and also 282.77 pg/mL (P<0.001) (stage 5), respectively.

Conclusion: The result of this study showed the vitamin D3 levels increased in all stages after 2 months. Also, the findings indicated that administration of vitamin D3 in all patients of the study groups reduced serum PTH levels. However, the rate of reduction was higher in stages 4 and 5 of CKD as compared to stages 2 and 3 of CKD (P<0.001).This result encourages us to prescribe supplement vitamin D3 if the level is less than 30 ng/mL.

Keywords: 25-Hydroxy vitamin D, PTH, Chronic kidney disease, Hemodialysis

Implication for health policy/practice/research/medical education:

In a study on 115 patients with stages 2 to 5 CKD and the age of more than 14 years old, we found vitamin D deficiency as the serum level of 25 (OH)D3 <30 ng/mL, is common in CKD patients. There was a positive correlation between the serum levels of 25(OH)D3 and levels of PTH. The findings indicated that administration of vitamin D3 in all CKD patients with vitamin D deficiency was effective in reducing the serum levels of PTH.

Please cite this paper as: Jalalzadeh M, Mousavinasab SN, Rostami A. Relationship of circulating levels of 25(OH)D with parathyroid hormone in various stages of chronic kidney disease. J Renal Inj Prev. 2017;6(4):264-268. DOI: 10.15171/jrip.2017.50.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 1933

Your browser does not support the canvas element.


PDF Download: 968

Your browser does not support the canvas element.